CRMD CorMedix Inc
Price (delayed)
$9.06
Market cap
$590.55M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.3
Enterprise value
$550.41M
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company is focused on developing its
Highlights
The EPS has surged by 67% year-on-year and by 63% since the previous quarter
CorMedix's net income has soared by 61% YoY and by 61% from the previous quarter
The quick ratio has shrunk by 54% YoY and by 11% QoQ
Key stats
What are the main financial stats of CRMD
Market
Valuations
Earnings
Shares outstanding
65.18M
Market cap
$590.55M
Enterprise value
$550.41M
Price to earnings (P/E)
N/A
Price to book (P/B)
6.49
Price to sales (P/S)
12.27
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12.66
Revenue
$43.47M
Gross profit
$40.28M
Operating income
-$22.36M
Net income
-$17.93M
EBIT
-$19.29M
EBITDA
-$18.98M
Free cash flow
-$50.73M
Per share
Balance sheet
Liquidity
EPS
-$0.3
EPS diluted
-$0.3
Free cash flow per share
-$0.86
Book value per share
$1.4
Revenue per share
$0.74
TBVPS
$1.99
Total assets
$118.85M
Total liabilities
$34.19M
Debt
$517,013
Equity
$84.66M
Working capital
$80.74M
Debt to equity
0.01
Current ratio
3.39
Quick ratio
3.05
Net debt/EBITDA
2.11
Margins
Efficiency
Dividend
EBITDA margin
-43.7%
Gross margin
92.7%
Net margin
-41.2%
Operating margin
-51.4%
Return on assets
-22.3%
Return on equity
-29%
Return on invested capital
-74.1%
Return on capital employed
-22.7%
Return on sales
-44.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CRMD stock price
How has the CorMedix stock price performed over time
Intraday
-0.44%
1 week
11.3%
1 month
34.42%
1 year
70.62%
YTD
11.85%
QTD
47.08%
Financial performance
How have CorMedix's revenue and profit performed over time
Revenue
$43.47M
Gross profit
$40.28M
Operating income
-$22.36M
Net income
-$17.93M
Gross margin
92.7%
Net margin
-41.2%
The company's net margin has surged by 89% QoQ
CorMedix's operating margin has surged by 88% QoQ
CorMedix's net income has soared by 61% YoY and by 61% from the previous quarter
The company's operating income has surged by 56% QoQ and by 54% YoY
Growth
What is CorMedix's growth rate over time
Valuation
What is CorMedix stock price valuation
P/E
N/A
P/B
6.49
P/S
12.27
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12.66
The EPS has surged by 67% year-on-year and by 63% since the previous quarter
The P/B is 55% above the 5-year quarterly average of 4.2 and 14% above the last 4 quarters average of 5.7
CorMedix's equity has increased by 44% QoQ and by 21% YoY
The price to sales (P/S) is 99% lower than the 5-year quarterly average of 1738.9
Efficiency
How efficient is CorMedix business performance
The return on sales has surged by 89% since the previous quarter
The ROA has soared by 66% from the previous quarter and by 65% YoY
The company's return on invested capital has surged by 65% QoQ and by 52% YoY
CorMedix's ROE has soared by 63% from the previous quarter and by 60% YoY
Dividends
What is CRMD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CRMD.
Financial health
How did CorMedix financials performed over time
CorMedix's total liabilities has surged by 187% YoY and by 81% QoQ
The quick ratio has shrunk by 54% YoY and by 11% QoQ
The company's debt is 99% lower than its equity
CorMedix's equity has increased by 44% QoQ and by 21% YoY
The company's debt fell by 23% YoY and by 7% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.